InDex Pharmaceuticals discontinues cobitolimod phase III program
Published on 08/07/2025 at 18:07 | prnewswire.co.uk
Independent Data Monitoring Committee (DMC) advises that cobitolimod is unlikely to meet the primary endpoint upon completion of Induction Study 1More information regarding next steps will be provided once a thorough analysis of the data from Induction Study 1 has been completedView original content:https://www.prnewswire.co.uk/news-releases/index-pharmaceuticals-discontinues-cobitolimod-phase-iii-program-301995261.html
en | boerse | 67937874 |
